AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05787210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadriceps Strength Training
Description: The experimental group will be administered with the same baseline treatment such as 5 minutes of trunk control training, 5 minutes walking in the hall with or without the therapist assistance, walker or crutches and 5 minutes breathing exercises for relaxation. In addition, they were given strength training protocol intervention other than the baseline treatment. This strength training protocol include progressive resistance training program in which we gave leg lift (knee flexion and extension), Hip rotations, seated marching and the quadriceps muscles would be specifically targeted.
Study NCT04121299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol 40mg Extended Release Once Daily
Study NCT04121299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 10mg Once Daily
Study NCT05154045 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test Meal
Description: Instant oatmeal
Study NCT05531630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal rinsing with saline 0.9%
Description: Nasal irrigations with saline (NaCl 0.9%) are considered golden standard in the treatment of chronic rhinosinusitis. Sachets consisting of mixtures for saline solutions, produced by DOS Medical®, consist of 1.875g sodium chloride and 0.625g sodium bicarbonate (figure 5). The content of the sachet has to be dissolved in 250mL heated water (lukewarm drinking water, max 37°C) in a NasoFree® nasal irrigator (Figure 4). Afterwards, the solution has to be mixed according to the instructions, the temperature has to be tested on the palm or forearm and afterwards, the product can be used. The patient will be asked to rinse their nose with the saline solution, once daily, for six weeks.~The sachet with rinsing salt is considered to be a class I medical device and has a CE-label (CNK number 3309028).
Study NCT05531630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal rinsing with Xylitol
Description: Xylitol is a sugar-alcohol that is already implemented in the treatment of patients with (difficult-to-treat) chronic rhinosinusitis. Some (pilot) studies have already showed a positive effect in CRS patients without cystic fibrosis. Xylitol nasal rinsing salt, produced by DOS Medical®, is a mixture of 4g Xylitol, 1.875g sodium chloride, 0.625g sodium bicarbonate and 0,03g mint (Figure 3). The content of the sachet has to be dissolved in 250mL heated water (lukewarm drinking water, max 37°C) in a NasoFree® nasal irrigator (Figure 4). Afterwards, the solution has to be mixed according to the instructions, the temperature has to be tested on the palm or forearm and afterwards, the product can be used. The patient will be asked to rinse their nose with the Xylitol solution, once daily, for six weeks.~The sachet with rinsing salt is considered to be a class I medical device, has a CE-label (CNK number 3309036) and is already commercially available in Belgium and The Netherlands.
Study NCT05639049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enova GF3
Description: Enova GF3, monofocal IOL
Study NCT05639049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis 1-piece ZCB00
Description: Tecnis 1-piece ZCB00, monofocal IOL
Study NCT06312839 — intervention group
Intervention type: OTHER
Intervention: Collecting data from the medical record
Description: Collecting data from the medical record:~* Gastroepiploic artery diameter before and after ischaemic preconditioning~* Postoperative mortality~* Complications related to embolisation and surgery~* Length of stay in intensive care unit and total length of hospital stay
Study NCT05520905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TelePrEP
Description: HIV pre-exposure prophylaxis delivered via telemedicine.
Study NCT04880759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bike desks in the classroom
Description: Children will use bike desks for 13 weeks during school time
Study NCT05222230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFP3 Mask
Description: Participans will wear FFP3 respirators during the study.
Study NCT05409599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Exercises
Study NCT04972006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote, intensive intervention for injection phobia
Description: The intervention consists of a 1.5 hour session that provides youth with education about anxiety and a 3 to 4 hour session consisting of graduated exposure to injection fear.
Study NCT05323500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Senobi breathing exercises
Description: The study participants will be screened first, then trained to perform SBE (1-minute maneuver). Participants will be instructed to stand upright and tighten their gluteal muscle and then ask them to put one foot in front of their body and placing most of their body weight on back foot. Then, ask them to breath in for three seconds simultaneously, by raising their hands in the air above their heads. After this, instruct them to exhale by using their whole body for pushing air out of the lungs. Participants will also guided to tighten all their body muscles while pushing air out. Exhale should last for seven seconds.
Study NCT05861440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: adjunct steroid per study protocol
Study NCT05861440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard anti-tuberculosis agents
Description: standard anti-tuberculosis agents
Study NCT05861440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard anti-tuberculosis agents
Description: standard anti-tuberculosis agents
Study NCT05742373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training in the fasted state
Description: Four weeks of moderate intensity cycling exercise, three times a week without eating breakfast meal
Study NCT05742373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training in the fed state
Description: Four weeks of moderate intensity cycling exercise, three times a week, after eating breakfast meal
Study NCT05287867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP)
Description: Approx 161-420cc autologous blood is drawn and processed into PPP, PRP, and PL, amount dependent on condition. Using sterile technique with patient sedated, US or x-ray is used to guide needles bilaterally into multifidus, specifically LM, TF, IAF. Once the lamina is reached the physician injects 2.5 cc of PPP into the multifidus muscle on one side and then repeat this on the opposite side for each level. The physician guides a needle into the supraneural transforaminal space to perform an epidural injection with 2cc of 4x PL and 1 cc of 0.5% ropivacaine. Next, a needle will then be guided into the facet joint to perform an intra-articular injection with 1cc of 14x PRP. Any tendon insertion areas will be injected using ultrasound guidance with platelet lysate dextrose. The supraspinous/interspinous, SI ligaments at the involved degenerative levels will be injected with 4x PL/12.5% dextrose/0.125% ropivacaine. If L5/S1 is involved, the iliolumbar ligaments will also be injected.
Study NCT05287867 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Approximately 161-420 cc of autologous blood is drawn to maintain patient blinding. While lying prone, the patient's back will be exposed and prepped sterilely.~Provider puts patient in conscious sedation and several needles are placed into the low back. The provider inserts needle into the facet joint and then removes. Then inserts the needle midline to ligament and removes (1 needle per level) mimicking normal needle placement, but not injecting anything.
Study NCT06577961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorolanib
Description: stage Ⅰ：Vorolanib 200mg QD stage Ⅱ：Vorolanib RP2D QD
Study NCT06577961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab
Description: stageⅠ：cadonilimab 10mg/kg Q3W stageⅡ：cadonilimab 10mg/kg Q3W
Study NCT06578052 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan liposome Capecitabine
Description: Irinotecan liposome: intravenous infusion, day 1, every 2 weeks Capecitabine: oral, twice daily (bid), days 1 to 7, take for one week and then have a one-week interval.~Each 2-week period is considered a treatment cycle, with an expected treatment of 6 cycles. Subsequent maintenance treatment will be determined by the investigator's protocol until disease progression or intolerable toxicity occurs.
Study NCT05220982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation Training Therapy
Description: Training clear speech in conversation with new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
Study NCT05220982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Global Voice Prevention and Therapy Model
Description: Training of four new voices (i.e., resonant voice in connected speech, falsetto for quiet talking, oral twang for talking over noise, and belt for healthy yelling) defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with new vs other or old voice at each step. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
Study NCT05220982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Conversation Training Therapy
Description: Training clear speech in conversation with no use of new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
Study NCT05220982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Global Voice Prevention and Therapy Model
Description: Training of a new resonant voice in connected speech defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with no use of new vs old voice. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
Study NCT05971784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Group
Description: The group that will receive upper extremity training via telerehabilitation in addition to an exercise program consisting of balance and walking activities
Study NCT05971784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The group that will receive an exercise program consisting of balance and walking activities
Study NCT05134259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
Study NCT04522011 — intervention group
Intervention type: OTHER
Intervention: intraoperative or postoperative hyperthermic intraperitoneal chemotherapy
Description: Intraoperative hyperthermic intraperitoneal chemotherapy：Use docetaxel + oxaliplatin Intraoperately.(Docetaxel 30mg/m2 + oxaliplatin 30mg/m2), perfusion at 43 ℃ for 1 hour
Study NCT05202613 — intervention group
Intervention type: DRUG
Intervention: Doravirine
Description: Doravirine, both as single drug and as fixed combination with lamivudine and tenofovir disoproxil fumarate
Study NCT05659706 — intervention group
Intervention type: OTHER
Intervention: cognitive evaluations and non cognitive evaluations
Description: Mini Mental State Examination Charlson Comorbidity Index Katz Index ICOPE step 1 The 15-item geriatric depression scale (GDS-15) Medical Outcomes Study Short Form 36 (SF-36) Short Physical Performance Battery ( SPPB)
Study NCT05028751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib
Description: Orally via tablets
Study NCT05028751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Orally via tablets
Study NCT06573684 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: All of groups will have assessment of electromyography result
Study NCT05241197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Load Training
Description: All participants in this arm will do two exercises, unilateral dynamic standing and sitting calf-raises, with a training load of 70% 1RM, being progressively increased by 5% every four weeks from 70% to 80%. This protocol will consist of three sets of 6-12 repetitions with a interset rest period of 1 minute and 3 minutes rest between exercises.
Study NCT06394531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jaboticaba Peel Extract
Description: Jaboticaba peel extract. Patients will ingest 4 capsules/day of jaboticaba (Plinia Cauliflora) peel extract, providing 3.3g of jabuticaba peel extract daily, containing 600mg of phenolic compounds, for one month.
Study NCT06394531 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. Patients will ingest 4 capsules/day of placebo (corn starch), providing 3.3g of placebo, for one month.
Study NCT05358561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed and Chia
Description: Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed, chia, flaxseed + chia and standart cakes
Study NCT04669704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Tablet application
Description: A protocol of exercises based on the current scientific evidence will be provided through a tablet application. A follow-up of the use of the application will be carried out. A minimum of 4-week home exercise intervention will be performed, which will have to be carried out daily by the patient autonomously at home for at least 5 days per week, starting after baseline measurement.~The exercise program will be individualized according to each pathology.
Study NCT04669704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Conventional treatment
Description: In the control condition, participants will receive a home exercise program on paper. The exercise program will be the conventionally prescribed one by the Andalusian Public Health Service. Participants will be told to perform exercises during a minimum of 4 week at home for at least 5 days per week, starting after baseline measurement.
Study NCT05841966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transoral Ultrasound
Description: The tonsils and tongue base will be scanned transorally using high-frequency intraoperative ultrasound transducers. Direct contact with the tonsils through the mouth is achieved during general anesthesia.
Study NCT05831995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABM-168
Description: Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration
Study NCT05207059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HELMS Lifestyle Intervention
Description: The HELMS life-course Interventions, namely 4S ('Screening', 'Size', 'Supplementation' and 'Specific case management'), are developed to deliver care throughout the journey from preconception to postpartum periods. Screening involves health and risk assessments through physical and biomarker measurements, as well as emotion and sleep evaluations for mother, and developmental assessment for children. Body Size management encompasses education on weight status awareness and mother-child health implications, both mother-child weight tracking, healthy eating and physical activity guidance. Supplementation includes multi-micronutrient, vitamin D, calcium and/or Docosahexaenoic acid (DHA) supplements, which is phase-specific for mother, and vitamin D drops supplement for child. Specific case management comprises preconception sexual health and function management, pregnancy symptoms management, postpartum recovery management, infant growth monitoring and feeding management.
Study NCT04853238 — intervention group
Intervention type: OTHER
Intervention: Prospective observational cohort study
Description: Prospective observational cohort study. No study treatment was administered in this study.
Study NCT05678699 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medicaid healthcare quality interventions (equity payment and obstetric bundled payment)
Description: This study has two components, with the first component being examined in Aim 1 and the first and second components being examine in aim 2.~1) health equity incentive payment program makes available $26 million annually in Medicaid managed care organization (MCO) payments to plans that improve access to timely prenatal care and well-child visits among Black beneficiaries. The equity-focused obstetric care bundled payment model provides incentives for clinicians to improve on a wide range of pregnancy health outcomes, and specifically incentivizes improvements among Black beneficiaries
Study NCT05678699 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Doula
Description: This study has two components, with the first component being examined in Aim 1 and the first and second components being examine in aim 2.~1. health equity incentive payment program makes available $26 million annually in Medicaid managed care organization (MCO) payments to plans that improve access to timely prenatal care and well-child visits among Black beneficiaries. The equity-focused obstetric care bundled payment model provides incentives for clinicians to improve on a wide range of pregnancy health outcomes, and specifically incentivizes improvements among Black beneficiaries.~2. care intervention by coverage of doula services for all Medicaid beneficiaries across Pennsylvania.
Study NCT05678699 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Participants receive standard care without quality interventions or doula care
Study NCT06442371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity interval training + Quranic Listening
Description: In this group, participants will receive protocol of High Intensity interval training which includes squats, jumping jacks, front kicks and rope jumps 3 days per week for 6 weeks, including warmup and cool down session along with Quranic listening meditation.
Study NCT06442371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training
Description: In this group, participants will receive only High intensity interval training which includes squats, jumping jacks, front kicks and rope jumps 3 days per week for 6 weeks, including warmup and cool down periods with no Quranic listening meditation
Study NCT06080035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Cetyl Tranexamate Mesylate
Description: Topical product will be applied onto clean skin morning and night.
Study NCT05972070 — intervention group
Intervention type: DEVICE
Intervention: ROMTech Portable Connect
Description: The ROMTech PortableConnect Rehab System is a continuous rehabilitative exercise therapy device that uses assisted movement to measure, evaluate, exercise, re-educate and strengthen muscles, and to increase joint range of motion.
Study NCT05001815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Description: The CSII device used in this study has access to mobile phone, however, without CGM enhanced function
Study NCT04693182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shift schedule without quick returns
Description: The intervention entails implementing a shift schedule which abolishes or substantially reduces the number of quick returns (less than 11 hours of rest between two shifts) for a six-month intervention period.
Study NCT06410040 — intervention group
Intervention type: DRUG
Intervention: Lorlatinib
Description: lolatinib 100mg qd po
Study NCT05001815 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple daily insulin injection (MDI)
Description: Patients with indication will receive MDI treatment with at least one basal insulin injection plus 2 to 3 prandial insulin injection.
Study NCT05195554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Description: Psycho-educational intervention will consist of between 10 and 12 people led by two professionals.
Study NCT05660473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Anti-tumor alkaloids
Study NCT05660473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Anthracycline
Study NCT05660473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Alkylating agent